Orthopaedic implants provider restor3d has secured $70m in a financing round for advancing the development of 3D printed implants.
The latest investment comprises a Series A funding worth $55m spearheaded by private investors including Summers Value Partners and existing investors, complemented by an additional $15m in debt financing from Trinity Capital.
This funding will be pivotal in accelerating the company’s growth and innovation, particularly in the development of new 3D-printed implant systems personalised for patients.
The company plans to introduce various patient-specific implant systems for total ankle and shoulder replacements, catering to the anatomical and pathological needs of individual patients.
restor3d aims to continue product advancements in its hip and knee portfolios, including a porous press-fit knee system enabled by 3D printing of both tibial and femoral components.
These systems are designed to offer improved patient outcomes and surgical efficiency.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Investments in advanced 3D printing technologies, software, and AI-based automation will also be a focus of the company.
restor3d seeks to expand its in-house ‘powder to sterile product’ production environment, which will not only increase the company’s capacity but also reduce personalised implant delivery times and production expenditures.
Furthermore, the new funding will facilitate the expansion of restor3d’s educational initiatives for providing training to surgeons and its sales team on the latest technologies and surgical techniques in orthopaedic and reconstructive surgery.
restor3d CEO Kurt Jacobus said: “This fundraising round is a testament to the confidence our investors have in restor3d’s vision and potential.
“With this capital, we can accelerate our efforts to transform orthopaedic care through 3D-printed personalised implants. We are eager to maximise our impact on patient outcomes and continue to advance orthopaedic care.”
In April 2023, the company obtained 510(k) clearance from the US Food and Drug Administration (FDA) for its Axiom patient-specific resection system for use with its Kinos Axiom Total Ankle System.
